Novartis India Limited has acquired the exclusive rights to promote and distribute NHPL's retina portfolio across India
This decision unlocks the opportunity to scale FPL’s established expertise in product development, manufacturing, and supply chain logistics directly into the pet-care industry
Renocia Exo offers a new multitargeted approach to hair loss management by supporting the biology of the hair follicle-not just hair growth
The buyback will be primarily funded through proceeds from Fosun Pharma’s disposal of approximately 6% of its equity stake in Gland Pharma, for total consideration of around US$294 million
Bhutan has recorded zero human deaths from dog-mediated rabies since June 2023
The technology targets some of the most difficult wounds to heal
The company's installed reactor capacity for API and CDMO has increased from 535 KL to 614 KL
The acquired portfolio includes Minipress XL (prazosin)
This decision follows a directive by Pfizer Inc. USA to cease the global manufacturing of the product
The company is committing Rs. 40–50 crore towards a dedicated custom peptide capacity programme through a strategic capacity underwriting arrangement
The partnership expands Tech Mahindra’s healthcare and life sciences business in North America and strengthens its positioning as a technology transformation partner for healthcare providers
The launch represents a significant expansion of the company’s business interests and comes as pharmaceutical companies increasingly seek opportunities across emerging and international markets
The deal gives Gan & Lee a major European partner as the Chinese pharmaceutical company seeks to turn bofanglutide into a global metabolic-health product
ZPUI has agreed to pay a total of US$ 5.9 million to resolve above litigation matters
The transaction marks RPGAP’s second strategic acquisition following its recent acquisition of Actis Generics
Priority-reviewed topical JAK inhibitor now approved for children as young as two, backed by Phase III data showing 63% response rate at eight weeks
The analysis is based on diagnostic testing trends across its network and tracks changes in disease positivity and geographic patterns
The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy
Subscribe To Our Newsletter & Stay Updated
